SMC
CORT icon

Smith, Moore & Co’s Corcept Therapeutics CORT Stock Holding History

Smith, Moore & Co’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$212K Buy
+2,440
New +$147K 0.01% 548
2025
Q4 		– Sell
-2,867
Closed -$238K – 533
2025
Q3 		$238K Hold
2,867
– – 0.02% 466
2025
Q2 		$210K Hold
2,867
– – 0.02% 483
2025
Q1 		$327K Buy
+2,867
New +$175K 0.03% 361

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Smith, Moore & Co's CORT Position: Q2 2026 in Review

Smith, Moore & Co opened a new position in Corcept Therapeutics (CORT) in Q2 2026: 2,440 shares worth $212K. The stake represents 0.01% of the portfolio and ranks #548 among its holdings. This is a return to the name: Smith, Moore & Co previously reported a position in CORT as recently as Q3 2025.

Smith, Moore & Co first reported a position in CORT in Q1 2025 and has held it in 4 quarters since. The position peaked at $327K in Q1 2025. 422 funds tracked by Wall St. Rank hold CORT as of Q2 2026.

  • Smith, Moore & Co held 2,440 shares of Corcept Therapeutics worth $212K as of Q2 2026.
  • Corcept Therapeutics was a new Smith, Moore & Co position in Q2 2026.
  • Corcept Therapeutics made up 0.01% of Smith, Moore & Co's portfolio in Q2 2026, its #548 holding.
  • Smith, Moore & Co first reported a position in Corcept Therapeutics in Q1 2025 and has held it in 4 quarters since.
  • Smith, Moore & Co's Corcept Therapeutics position peaked at $327K in Q1 2025.
  • 422 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2026.

Based on Smith, Moore & Co's 13F filing for Q2 2026, filed 12 Aug 2026.